Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature

FOLFOXIRI plus bevacizumab (BV) versus FOLFIRI plus BV as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary safety results of the phase III randomized TRIBE study by the Gruppo Oncologico Nord-Ovest (GONO).

(2017) A. Falcone et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized two-arm phase III study to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) versus CAPOX alone in post radical resection of patients with liver metastases of colorectal cancer.

(2017) E. E. Voest et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of the type and modalities of preoperative chemotherapy on the outcome of liver resection for colorectal metastases.

(2017) R. Adam et al.   JOURNAL OF CLINICAL ONCOLOGY

Intermittent chemotherapy (CT) plus continuous or intermittent cetuximab (C) in the first-line treatment of advanced colorectal cancer (aCRC): Results of the two-arm phase II randomized MRC COIN-B trial.

(2017) Harpreet Wasan et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study

(2012) E. Diaz-Rubio et al.   ONCOLOGIST

A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection

(2011) R. Wong et al.   ANNALS OF ONCOLOGY

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

(2011) C. Bokemeyer et al.   ANNALS OF ONCOLOGY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen

(2011) Lorenzo Fornaro et al.   Clinical Colorectal Cancer

Incidence of synchronous liver metastases in patients with colorectal cancer in relationship to clinico-pathologic characteristics. Results of a German prospective multicentre observational study

(2011) R. Mantke et al.   EJSO

Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?

(2011) Fabrice Andre et al.   JOURNAL OF CLINICAL ONCOLOGY

Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer

(2011) Daniel G. Haller et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

(2011) Timothy S Maughan et al.   LANCET

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

(2011) Richard A Adams et al.   LANCET ONCOLOGY

Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial

(2011) E. Assenat et al.   ONCOLOGIST

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study

(2010) Gemma Bruera et al.   BMC CANCER

Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis

(2010) R Zarate et al.   BRITISH JOURNAL OF CANCER

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial

(2010) C Garufi et al.   BRITISH JOURNAL OF CANCER

Surgical management and outcomes of colorectal cancer liver metastases

(2010) E. J. A. Morris et al.   BRITISH JOURNAL OF SURGERY

Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series

(2010) A. E. M. van der Pool et al.   Colorectal Disease

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

(2010) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

(2010) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

(2010) Gianluca Masi et al.   LANCET ONCOLOGY

Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel

(2009) B. Nordlinger et al.   ANNALS OF ONCOLOGY

A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer

(2009) M. Ychou et al.   ANNALS OF ONCOLOGY

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

(2009) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study

(2009) Benoist Chibaudel et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy

(2009) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

(2009) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

(2009) Gunnar Folprecht et al.   LANCET ONCOLOGY

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE

Optimising the design of phase II oncology trials: The importance of randomisation

(2008) Mark J. Ratain et al.   EUROPEAN JOURNAL OF CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Urgent Need for a New Staging System in Advanced Colorectal Cancer

(2008) Graeme J. Poston et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials

(2008) Emmanuel Mitry et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer

(2008) Brigit Gruenberger et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)

(2008) Axel Grothey et al.   JOURNAL OF CLINICAL ONCOLOGY

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

(2008) J. Randolph Hecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

(2008) Bernard Nordlinger et al.   LANCET